SEC Tracker
Get the app

Akebia Therapeutics AKBA

Akebia Therapeutics faces Nasdaq delisting risk

Item 3.01 Listing standards notice

Form
8-K
Filed
Importance
Major
  1. Received Nasdaq deficiency letter for bid price below $1.00
  2. 180-day compliance period until April 19, 2027
  3. May need reverse stock split to regain compliance

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Akebia Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Viridian Therapeutics VRDN public float $943M, Jun 30, 2025
  2. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  3. Ardelyx ARDX public float $924M, Jun 30, 2025
  4. Neogen NEOG public float $972M, Nov 30, 2025
  5. CorMedix CRMD public float $910M, Jun 30, 2025